Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
Open Access
- 23 May 2025
- journal article
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (2) , 243-251
Abstract
Oncological diseases are one of the leading causes of mortality in the world. Despite the intensive search for new methods to increase the efficacy and safety of antineoplastic therapy and to reduce resistance to it by malignant tumors, treatment issues still remain unresolved in clinical oncology. This review analyses experimental data on the antineoplastic effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors: the reasons why SGLT2 inhibitors can be used for the treatment of malignant tumors are presented, class-specificity and dose-dependence of the antineoplastic effect of the drugs are determined. Possible mechanisms of antitumor effect of glyflozins are described in detail, among which, in addition to reduction of glucose entry into tumor cells, inhibition of Wnt/β-catenin signalling pathway, enhancement of AMP activated protein kinase activity with subsequent change of lipid profile of tumor cells and inhibition of mTOR protein kinase (mammalian target of rapamycin), disruption of DNA and RNA synthesis in malignant tumor cells, etc. play a significant role. Considerable space is devoted to the pro-oncogenic effect of SGLT2 inhibitors, previously undisputed and now disproved, as well as to the interaction of this class of antidiabetic agents with other antitumor treatment in the context of efficacy, safety and therapeutic resistance.Keywords
This publication has 52 references indexed in Scilit:
- Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: An additional anti-tumor effect of the drugBiomedicine & Pharmacotherapy, 2023
- Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1αMolecular Oncology, 2023
- Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humansBiomedicine & Pharmacotherapy, 2022
- Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new applicationBiomedicine & Pharmacotherapy, 2022
- The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis–associated liver tumors in a novel murine modelBiomedicine & Pharmacotherapy, 2021
- Glucose Metabolism in Cancer: The Warburg Effect and Beyond2021
- Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitroDiabetology International, 2021
- Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathwayBiomedicine & Pharmacotherapy, 2020
- Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicinBiochemical Pharmacology, 2020
- SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trialsDiabetologia, 2017